Evaluation of CD43 expression in non-hematopoietic malignancies

Batdorf, Bjorn; Kroft, Steven H.; Hosking, Paul; Harrington, Alexandra M.; Mackinnon, Alexander C.; Olteanu, Horatiu

doi:10.1016/j.anndiagpath.2017.04.010

Cited by 9 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immune checkpoints include PD-1, TIGIT, CTLA-4, LAG-3, CD27, BTLA, TIM-3, and 1B11. Their related binding partners were PD-L1/PD-L2, CD155 (PVR), CD80/CD86, FGL1/HLA-DR, CD70, HVEM, galectin-9 (Gal-9), and CD43, respectively [ 27 , 28 , 29 ]. The expression of the different immune-checkpoint-related binding partners in various lung cancer cell lines is shown in Figure 3 .…”

Section: Resultsmentioning

confidence: 99%

Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer

Luo

Yang

Chien

et al. 2021

IJMS

View full text Add to dashboard Cite

Lung cancer is the leading cause of death from cancer in Taiwan and throughout the world. Immunotherapy has revealed promising and significant efficacy in NSCLC, through immune checkpoint inhibition by blocking programmed cell death protein (PD)-1/PD-1 ligand (PD-L1) signaling pathway to restore patients’ T-cell immunity. One novel type of long, non-coding RNAs, circular RNAs (circRNAs), are endogenous, stable, and widely expressed in tissues, saliva, blood, urine, and exosomes. Our previous results revealed that the plasma level of hsa_circ_0000190 can be monitored by liquid-biopsy-based droplet digital PCR and may serve as a valuable blood-based biomarker to monitor the disease progression and the efficacy of immunotherapy. In this study, hsa_circ_0000190 was shown to increase the PD-L1 mRNA-mediated soluble PD-L1 (sPD-L1) expression, consequently interfering with the efficacy of anti-PD-L1 antibody and T-cell activation, which may result in immunotherapy resistance and poor outcome. Our results unraveled that hsa_circ_0000190 facilitated the tumorigenesis and immune evasion of NSCLC by upregulating sPD-L1 expression, potentially developing a different aspect in elucidating the molecular immunopathogenesis of NSCLC. Hsa_circ_0000190 upregulation can be an effective indicator for the progression of NSCLC, and hsa_circ_0000190 downregulation may possess a potential therapeutic value for the treatment of NSCLC in combination with immunotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer

Luo

Yang

Chien

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…It is considered as a marker of hematopoietic cells and is highly expressed in acute myeloid leukemia and myelodysplastic syndromes ( Rosenstein et al, 1999 ). It is also highly expressed in various solid malignant tumors, and it is related to tumor promotion ( Balikova et al, 2012 ; Batdorf et al, 2017 ). More importantly, CD43s is overexpressed in melanoma cell lines and patients’ melanoma samples.…”

Section: Basic Characteristics Of Bispecific Antibodiesmentioning

confidence: 99%

Bispecific Antibodies Progression in Malignant Melanoma

Tang

Gong

2022

Front. Pharmacol.

View full text Add to dashboard Cite

The discovery of oncogenes and immune checkpoints has revolutionized the treatment of melanoma in the past 10 years. However, the current PD-L1 checkpoints lack specificity for tumors and target normal cells expressing PD-L1, thus reducing the efficacy on malignant melanoma and increasing the side effects. In addition, the treatment options for primary or secondary drug-resistant melanoma are limited. Bispecific antibodies bind tumor cells and immune cells by simultaneously targeting two antigens, enhancing the anti-tumor targeting effect and cytotoxicity and reducing drug-resistance in malignant melanoma, thus representing an emerging strategy to improve the clinical efficacy. This review focused on the treatment of malignant melanoma by bispecific antibodies and summarized the effective results of the experiments that have been conducted, also discussing the different aspects of these therapies. The role of the melanoma epitopes, immune cell activation, cell death and cytotoxicity induced by bispecific antibodies were evaluated in the clinical or preclinical stage, as these therapies appear to be the most suitable in the treatment of malignant melanoma.

show abstract

“…CD43, expressed highly on haematopoietic cells, has also been shown to be aberrantly expressed in solid tumours, such as colon and breast cancer. 66,67 This suggests that CD43 can also be targeted in solid tumours. We have demonstrated that AT1413 can be used to target CD43s-expressing melanoma cells (De Jong et al, manuscript in preparation).…”

Section: Tumour-associated Antigens Are Shared Between Solid and Haemmentioning

confidence: 99%

Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation

Jong

Gillissen

Spits

et al. 2020

Immuno-Oncology Technology

View full text Add to dashboard Cite

For many high-risk haematologic malignancies, such as acute myeloid leukaemia, the success of therapy relies mainly on invoking a curative antitumour immune response. This can be achieved by inducing a graft-versus-leukaemia response following allogeneic haematopoietic cell transplantation. While the contribution of T cells and natural killer cells to graft-versus-leukaemia responses is established, the contribution of B cells and antibodies is relatively unexplored. This article reviews what is known about the contribution of B cells and tumour-specific antibody responses to a successful graft-versus-leukaemia response leading to eradication of the tumour.

show abstract

Evaluation of CD43 expression in non-hematopoietic malignancies

Cited by 9 publications

References 22 publications

Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer

Circular RNA hsa_circ_0000190 Facilitates the Tumorigenesis and Immune Evasion by Upregulating the Expression of Soluble PD-L1 in Non-Small-Cell Lung Cancer

Bispecific Antibodies Progression in Malignant Melanoma

Tumour-reactive B cells and antibody responses after allogeneic haematopoietic cell transplantation

Contact Info

Product

Resources

About